Home
Research
Submit Article
News
Sectors
Advertise
Premium
i On The Market - Daily Newsletter
Every trading day, be ready to attack the market instead of reacting to the market.
You will know where the key technical resistance and support levels are and what the market is likely to do next. iStock will arm you with a target list of stocks to buy and sell - right now - based on our exclusive, proprietary trading models.
Two Week FREE Trial
About Us
About Us
Editorial Staff
Terms and Conditions
Privacy Policy
Contact Us
iStock Rating
C
Details...
Enter Symbol
Vical Incorporated (NASDAQ: VICL)
Sector: Medical
Current Price :
$3.11
52 Week Low
$2.74
52 Week High
$4.58
Company
Overview
Research Notes
Company Profile
Competitors
Community
Stock Sentiment
Whisper Estimates
Enter Estimates
Analysis
Blog Articles
Press Releases
Charts
Technical Charts
Analyst
Analyst Ratings
Analyst Estimates
Sales Estimates
Ratios
Financial Ratios
Technicals
Press Releases
Vical to Present at Wells Fargo Securities Healthcare Conference
Vical Appoints Richard M. Beleson and Stephen A. Sherwin, M.D., to Board of Directors
Vical Reports First Quarter 2013 Financial Results and Progress in Key Development Programs
Vical to Present at May Investor Conferences
Vaxfectin(R) Enhances Preclinical Immune Responses to Baxter's Cell Culture-Derived Influenza Vaccines
Vical Announces News Release and Conference Call Schedule for First Quarter 2013 Financial Results
Vical CEO to Participate in Cancer Immunotherapy Panel at BIO International Convention
Vical to Present at March Investor Conferences
Vical Reports 2012 Financial Results and Progress in Key Development Programs
Vical to Present at February Investor Conferences
Vical Announces Publication of Herpes Simplex Vaccine Guinea Pig Study Data
Biotech Industry Expected to Experience More Merger & Acquisition Activity in 2013
Vical Announces News Release and Conference Call Schedule for 2012 Financial Results
Vical to Present at 31st Annual J.P. Morgan Healthcare Conference
Vical Licenses Vaxfectin(R) Adjuvant to Cyvax for Use in Malaria Vaccines
Vical to Present at Credit Suisse 2012 Healthcare Conference
Preclinical Data Support Potential Combinations for Allovectin(R) With Emerging Immunotherapies
Vical Reports Third Quarter 2012 Financial Results and Progress in Key Development Programs
Vical Names Mammen P. Mammen, Jr., M.D., Vice President, Clinical Vaccines
Vical Announces News Release and Conference Call Schedule for Third Quarter 2012 Financial Results
Vical Appoints George J. Morrow to Board of Directors
Vical to Present at 3rd Annual Cancer Immunotherapy Conference
Vical Licenses DNA Immunization Technology and Vaxfectin(R) Adjuvant to Bristol-Myers Squibb for Use in Antibody Production
Vical to Present at September Investor Conferences
Vical to Present at Canaccord Genuity Annual Growth Conference
International Law Firm Winston & Strawn Retained as Counsel for Immunovative, Inc.
Vical Reports Second Quarter 2012 Financial Results and Progress in Key Development Programs
Vical Announces News Release and Conference Call Schedule for Second Quarter 2012 Financial Results
Vical to Present at JMP Securities Healthcare Conference
Vical to Present at Wells Fargo Securities Healthcare Conference
Vical Announces Publication of Herpes Simplex Vaccine Mouse Study Data
Vical Updates Herpes Simplex Vaccine Development at ASGCT Conference
Vical to Present at Upcoming Investor Conferences
Vical Reports First Quarter 2012 Financial Results and Progress in Key Development Programs
Vical Announces News Release and Conference Call Schedule for First Quarter 2012 Financial Results
Astellas and Vical Advance Toward Phase 3 Trial of TransVax(TM) CMV Vaccine Triggering $10 Million Milestone Payment to Vical
Novel Transmission-Blocking Malaria DNA Vaccine Candidate Uses Vical's Vaxfectin(R) Adjuvant
U.S. Navy Advances Dengue DNA Vaccine Using Vical's Vaxfectin(R) Adjuvant
Vical to Present at Upcoming Investor Conferences
Vical to Present at Upcoming Investor Conferences
Vical Reports 2011 Financial Results and Progress in Key Development Programs
Vical Announces News Release and Conference Call Schedule for 2011 Financial Results
Vical Presents Case Study on Successful Design of Allovectin(R) Phase 3 Melanoma Trial
Vical to Present at Credit Suisse 2011 Healthcare Conference
Vical Reports Third Quarter 2011 Financial Results and Progress in Key Development Programs
Vical Announces News Release and Conference Call Schedule for Third Quarter 2011 Financial Results
Vical to Present at NewsMakers Conference
Vical Reports Prophylactic and Therapeutic Efficacy With Herpes Simplex Vaccines in Guinea Pig Model
Global Situation & Resulting Influences - Research Report on Vical Incorporated and Life Technologies Corp.
Allovectin(R) Demonstrates Synergistic Efficacy With Anti-CTLA-4 Antibody in Melanoma Animal Model
Vical Announces Key International Patents for Vaxfectin(R) Adjuvant
Vical to Present at September Investor Conferences
Vical Provides Vaxfectin(R) Review at Novel Vaccines: Adjuvants & Delivery Systems Conference
Vical Reports Second Quarter 2011 Financial Results and Progress in Key Development Programs
Vical Announces Early Termination of Hart-Scott-Rodino Waiting Period for TransVax(TM) License Agreements With Astellas
Vical Reports Successful Nonclinical Results With Vaxfectin(R) Adjuvant
Vical and Astellas Announce Worldwide License Agreements for TransVax(TM) Cytomegalovirus Vaccine
Vical Announces Scientific Advances for Multiple Programs at DNA Vaccines 2011 Conference
Vical Provides Allovectin(R) and Herpes Simplex Vaccine Updates at BIO International Convention
Vical Presents Positive Correlation Between Response and Survival at ASCO for Completed Allovectin(R) Melanoma Trials
Vical to Present at Jefferies Global Healthcare Conference
Vical Presentations on TransVax(TM) and DNA Vaccines at ASGCT Conference
Presentations by Vical and Collaborators at CMV/BetaHerpesvirus Workshop
Vical to Present at Noble Financial Capital Markets Conference
Vical to Present at Bank of America/Merrill Lynch Health Care Conference
Vical Reports First Quarter 2011 Financial Results and Progress in TransVax(TM) and Allovectin(R) Programs
Vical and the University of Washington Receive Additional U.S. Patent for Herpes Simplex Vaccine
Vical Announces News Release and Conference Call Schedule for First Quarter 2011 Financial Results
Vical Announces Encouraging H1N1 Pandemic Influenza Vaccine Phase 1 Results
Vical Announces Key European Patent for TransVax(TM) Cytomegalovirus Vaccine
Vical to Participate in Leerink Swann Cancer Roundtable Conference
Vical to Present at ROTH Growth Stock Conference
Vical Receives Positive Scientific Advice From EMA for TransVax(TM) Phase 3 Trial
Vical to Present at Upcoming Investor Conferences
Vical Extends Collaboration With U.S. Government for Emerging Disease Vaccines
Vical Receives U.S. Patent for Cytomegalovirus Vaccines
Vical's Allovectin-7(R) Phase 3 Trial Receives Positive Review from Safety Monitoring Board
Vical Reports 2010 Financial Results and Progress in Key Development Programs
Vical and the University of Washington Receive U.S. Patent for Herpes Simplex Vaccine
Vical Announces News Release and Conference Call Schedule for 2010 Financial Results
Publication Highlights Allovectin-7(R) Phase 2 Safety and Efficacy Results in Melanoma
Fundamental data is provided by
Zacks Investment Research
, and Commentary, news and Press Releases provided by YellowBrix and
Quotemedia
. Advertisement partners
Investing Channel
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##